Dr. Antoni Chan synovialjoints
2 years 4 months ago
GC treatment duration for <90 and 90 to 360 days is associated with a higher risk of cumulative SI compared to nonexposed, especially the first year but also up to two years since first visit in RA patients. Maximum RR for <90 days is observed at 8 months since first visit (RR:… https://t.co/ecK2ylqrRk https://t.co/IQ5QQjExYQ
Dr. Antoni Chan synovialjoints
2 years 4 months ago
Poster tours at #EULAR2024.
A third of seropositive RA patients with long disease duration had subclinical lung abnormalities. This pilot study showed the potential role of lung ultrasound for the screening of subclinical ILD among these patients. Abstract 070 @RheumNow https://t.co/ypAh4idV3j
Janet Pope Janetbirdope
2 years 4 months ago
Who needs intensive therapy in #lupus
Intensive Rx in #SLE from 2 inception cohorts in Leeds
Either #Cyclo or #biologics
⬆️
If low complement
Within 2 yrs after #dx
#SLEDAI >9
AntiRo+
OP0187
#EULAR2024 @RheumNow @eular_org https://t.co/oKhwMmHhSs
Janet Pope Janetbirdope
2 years 4 months ago
Top 3 messages
Re
#JAKi #safety
Shared decision w benefit/risk info
Some #CV risks are more Impt than others- stratify your pt into risk categories
#Smoking is a big risk for #MACE &
#malignancy-So work on facilitating
Smoking #cessation
#EULAR2024 @eular_org @RheumNow
Janet Pope Janetbirdope
2 years 4 months ago
3 facts in #lupus to make you think 🤔
💧biomarkers in #SLE blood & #urine May predict #activity
OP0255
#Membranous #nephritis is serious in SLE @ZahiTouma POS0732
#prednisone dose irrelevant for #damage if in LLDAS -no diff between 7.5mg vs 5mg OP0124
#EULAR2024 @RheumNow
Janet Pope Janetbirdope
2 years 4 months ago
#Hope for patients with #active #SLE
The next hurdle is getting through
▶️Phase3 #RCTs
And
▶️Obtaining drug reimbursement so patients can get access to effective
#lupus #Rx
#EULAR2024
@RheumNow @eular_org https://t.co/sGzQXO4A2r
Mrinalini Dey DrMiniDey
2 years 4 months ago
OP0072 @RheumNow #EULAR2024
Effects of #Upadacitinib or #Adalimumab on pain in #RA
SELECT-COMPARE Phase 3 study
UPA & ADA led to improvements in pain vs PBO
PtGA & TJC28 pain improvement similar between UPA & ADA
➡️ UPA may be more effective in control of pain than ADA in RA
Dr. Antoni Chan synovialjoints
2 years 4 months ago
Can we prevent psoriatic arthritis? Highlights from #EULAR2024 that help us understand this topic better @RheumNow https://t.co/E8Wy8FH4oU
Janet Pope Janetbirdope
2 years 4 months ago
#Vaccinations against #herpes #zoster in #MTX +#Upadacitinib Pts
▶️ #Shingrix works
👍Pts followed to 60 months
#EULAR2024
@eular_org @RheumNow
#OP0020 https://t.co/8ORC3Nd2FK
Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how early interventions in PsO may augment the progression to PsA. At #EULAR2024, there are a few presentations on this topic that will help us understand this progression from PsO to PsA better.
Several abstracts are presenting new compounds, targeting either RA well-known inflammatory pathways or offering new mechanisms of action or therapeutic sequences; these are summarized below.
